CERENOME, INC.
Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. Its wholly owned subsidiary, CNSide Diagnostics, develops and commercializes laboratory-developed tests, including the CNSide Test, which detects and characterizes tumor cells in cerebrospinal fluid. The company also develops rhenium (186Re) obisbemeda, an investigational radiotherapy for central nervous system cancers, and 188RNL-BAM, a preclinical radiotherapeutic device intended for solid organ cancers, initially liver cancer. Plus Therapeutics makes money through its diagnostic testing business and intends to commercialize its therapeutic products if developed and approved. The CNSide Test is provided through a centralized laboratory in Houston, where the company is headquartered. Plus Therapeutics also works with third parties to develop, manufacture and supply its radiotherapeutic product candidate.
No SEC Form 4 filings for $CNSY in the last 30 days.
See all $CNSY insider activity →Cerenome, Inc. (CNSY) completed enrollment in its Phase 2 ReSPECT-GBM study for recurrent glioblastoma. Interim data showed a 13-month median survival. Topline data is expected mid-2027. The trial evaluates REYOBIQ, a radiotherapeutic designed to deliver targeted radiation. The company aims to discuss results with the FDA afterward.
Cerenome, Inc. (Nasdaq: CNSY) will present interim data from its ReSPECT-LMM study of REYOBIQ for leptomeningeal metastases at the SNO 31st Annual Meeting. The study, with 10 patients, aims to advance to a Phase 2 dose randomization study in 2027. Cerenome will also host a symposium on CNS cancer diagnosis and treatment.
Cerenome, Inc. (CNSY) presented preclinical data at the 16th Biennial Rivkin Ovarian Cancer Research Symposium, showing that REYOBIQ, its lead investigational radiotherapeutic, demonstrated tumor injury and immune activation in mouse models of ovarian cancer. Combination treatment with anti-PD-1 checkpoint blockade extended median survival to 65 days, suggesting potential for REYOBIQ in enhancing immunotherapy effectiveness.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CNSY (CERENOME, INC.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent CNSY coverage spans financial news, technology and corporate actions.
Enrollment completion removes a key execution risk and sets the stage for data read‑out, which could move the stock if results are positive.
The interim data could influence investor sentiment on CNSY, with positive results driving upside and any safety concerns prompting downside.
Positive preclinical results suggest potential for future clinical success and may boost investor sentiment.
The new payer contract should boost revenue visibility and may drive the stock higher.
The launch adds a new revenue stream and may boost the stock as investors price in expanded test offerings.
AlphAI scores every news story that mentions CNSY with an AI model for sentiment and relevance, and aggregates insider trades from CERENOME, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cerenome, Inc. (CNSY) completed enrollment in its Phase 2 ReSPECT-GBM study for recurrent glioblastoma. Interim data showed a 13-month median survival. Topline data is expected mid-2027. The trial evaluates REYOBIQ, a radiotherapeutic designed to deliver targeted radiation. The company aims to discuss results with the FDA afterward.
1 min readCerenome, Inc. (Nasdaq: CNSY) will present interim data from its ReSPECT-LMM study of REYOBIQ for leptomeningeal metastases at the SNO 31st Annual Meeting. The study, with 10 patients, aims to advance to a Phase 2 dose randomization study in 2027. Cerenome will also host a symposium on CNS cancer diagnosis and treatment.
2 min readCerenome, Inc. (CNSY) presented preclinical data at the 16th Biennial Rivkin Ovarian Cancer Research Symposium, showing that REYOBIQ, its lead investigational radiotherapeutic, demonstrated tumor injury and immune activation in mouse models of ovarian cancer. Combination treatment with anti-PD-1 checkpoint blockade extended median survival to 65 days, suggesting potential for REYOBIQ in enhancing immunotherapy effectiveness.
2 min readCerenome, Inc. (CNSY) reached an in-network agreement with Florida Blue for its CNSide tests, adding ~6M covered lives and totaling ~164M. The deal is effective Oct 1, 2026, according to the company.
1 min readCerenome's subsidiary, CNSide Diagnostics, launched two new CSF-based molecular profiling tests for cancer on October 12, 2026. The tests analyze DNA and RNA from cerebrospinal fluid, expanding the patient population served. The launch follows a peer-reviewed study showing molecular findings in 78.4% of specimens. Cerenome (Nasdaq: CNSY) aims to integrate diagnostics, therapeutics, and AI for CNS oncology.
2 min readCerenome updated its investor presentation, reporting CNSide commercial progress with 24 ordering institutions and 362 tests YTD. It also highlighted upcoming REYOBIQ Phase 2 readouts and expected Medicare pricing in 2027. The company has 158M contracted covered lives and is building a 11,000-test CSF library.
1 min readCerenome (CNSY) reported Q3 2026 gross billings of $1.55M for CNSide Diagnostics. The company expects to cover 200M lives by early 2027 and launch new tests in Q4 2026. Annualized billing run rate is projected to reach $10M-$12M by Q4 2026, according to management.
2 min readADARx (ADRX) priced its IPO at $17/share, raising $446.3M, with AbbVie investing $100M. CNSY (CNSY) secured reimbursement with Blue Cross Blue Shield. JAGX (JAGX) completed a reverse stock split. AGL (AGL) expanded its partnership with Springfield Clinic. ONCO (ONCO) agreed to acquire Realbotix. All stocks traded higher.
2 min readCerenome's subsidiary CNSide Diagnostics signed an in-network agreement with Blue Cross Blue Shield of Michigan, expanding coverage to 5 million members. This deal increases CNSide's reimbursement coverage to 158 million lives nationwide, supporting physician adoption and patient access. Cerenome's stock is up 6.84% at $2.03.
1 min readCERENOME, INC. (CNSY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Capital will support continued CNSide ® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash r
1 min read
